One Case of Acute Drug-Induced Liver Injury Caused by Cyclophosphamide for Injection in a Patient with Relapsing Polychondritis

doi:10.19803/j.1672-8629.20240830

Abstract

Abstract: Objective To analyze the acute drug-induced liver injury caused by low-dose cyclophosphamide for injection in a patient with relapsing polychondritis so as to provide a reference for clinicians. Methods The clinical data of a patient with relapsing polychondritis who developed acute drug-induced liver injury after the first low-dose intravenous application of cyclophosphamide was analyzed. The related literature was reviewed. Results The patient presented with acute liver injury after the first low-dose intravenous application of cyclophosphamide. After correlation analysis and multidisciplinary consultation, the patient was diagnosed with acute cyclophosphamide-induced liver injury. Cyclophosphamide was discontinued, and liver protection therapy was initiated, which led to a good prognosis. Conclusion Individual differences in adverse reactions deserve attention among patients who use cyclophosphamide for the first time. This drug should be used with caution. It is critical to identify the risk factors and assess the type and severity of cyclophosphamide induced liver injury so as to adjust the treatment in time.

Key words: Cyclophosphamide, Injection, Relapsing Polychondritis, Acute Drug-Induced Liver Injury, Liver Function, Adverse Drug Reactions

CLC Number:

LIU Hong, WANG Qian, CHENG Yongjing, CHEN Yingjuan. One Case of Acute Drug-Induced Liver Injury Caused by Cyclophosphamide for Injection in a Patient with Relapsing Polychondritis[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1162-1164.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240830

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I10/1162

References

[1] PATIAS NS, SINHORIN VDG, FERNEDA AJLB, et al.Study of Liposomes Containing Extract from the Leaves of Protium Heptaphyllum (Aubl.) March in Animals Submitted to a Mutagenic Model Induced by Cyclophosphamide[J]. Biology (Basel), 2024, 13(9): 706.
[2] MURATORI L, FERRARI R, MURATORI P, et al.Acute Icteric Hepatitis Induced by a Short Course of Low-Dose Cyclophosphamide in a Patient with Lupus Ne-Phritis[J]. Digestive Diseases and Sciences, 2005, 50(12): 2364-2365.
[3] DECHIARA JR, BIRCH EM, HARPER H.Low-Dose Cyclophosphamide Associated with Hyponatremia and Hepatotoxicity[J]. Cureus, 2023, 15(9): e45375.
[4] LYU BB, LIU XM, YAN JJ, et al.Incidence, Clinical Features, Mechanism and Prevention of Immunosuppressive Agents-Related Liver Injury[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2023, 43(18): 2015-2019, 2112.
[5] ZHAO F, ZHANG LN, WANG YY.Acute Liver Injury Induced by Cyclophosphamide Treatment of Resistant Dermatomyositis: a Case Report and Review of Literature[J]. Clinical Medication Journal(临床药物治疗杂志), 2019, 17(8): 23-25.
[6] ANTONIOS K, SHAHEEN A, DUTTA P, et al.Acute Liver Injury Caused by Cyclophosphamide in a Patient with Factor VIII Deficiency: a Rare Presentation[J]. Cureus, 2024, 16(3): e55717.
[7] XU S, JIN PF, XU WF, et al.Advances on Analytical Methods of Cyclophosphamide[J]. Northwest Pharmaceutical Journal(西北药学杂志), 2023, 38(2): 223-226.
[8] Autoimmune Diseases Group, Dermatologists Branch, China Medical Doctor Association. Chinese Expert Consensus on Cyclophosphamide for the Treatment of Autoimmune Dermatoses[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2021, 54(9): 765-770.
[9] NHC. Measures for the Administration of Adverse Drug Reaction Reporting and Monitoring Order of the Ministry of Health of the People's Republic of China No. 81[EB/OL]. (2011-05-04)[2025-01-01]. https://www.nhc.gov.cn/zwgk/wlwl/201105/b442a66fc52b4793a57160002ac2a1a9.shtml.
[10] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association, Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese Guideline for Diagnosis and Management of Drug-Induced Liver Injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[11] YANG SY, GAO SQ, XIAO Y, et al.Prophylactic Effect and Mechanism of Protocatechuic Aldehyde on Cyclophosphamide-Induced Acute Liver Injury[J]. Chinese Traditional and Herbal Drugs(中草药杂志), 2024, 55(22): 7714-7723.
[12] ABDELFATTAH HA, SHALABY SI, KHATER SI, et al.Panax Ginseng Is Superior to Vitamin E as a Hepatoprotector against Cycloph-osphamide-Induced Liver Damage[J]. Complementary Therapies in Medicine, 2019, 46: 95-102.
[13] EL-SERAFI I, STEELE S.Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics[J]. Advances in Pharmacological and Pharmac-eutical Sciences, 2024, 2024: 4862706.
[14] PINTO N, LUDEMAN SM, DOLAN ME.Drug Focus: Pharma-Cogenetic Studies Related to Cyclophosphamide-Based Therapy[J]. Pharmacogenomics, 2009, 10(12): 1897-1903.
[15] ATTIA DS, EISSA M, SAMY LA, et al.Influence of Glutathione S Transferase A1 Gene Polymorphism (-69C>T, rs3957356) on Intravenous Cyclophosphamide Efficacy and Side Effects: a Case-control Study in Egyptian Patients with Lupus Nephritis[J]. Clinical Rheumatology, 2021, 40(2): 753-762.
[16] ZHONG S, HUANG M, YANG X, et al.Relationship of Glutathione S-Transferase Genotypes with Side-Effects of Pulsed Cyclophos-phamide Therapy in Patients with Systemic Lupus Erythematosus[J]. British Journal of Clinical Pharmacology, 2006, 62, 457-472.
[17] EKHART C, RODENHUIS S, SMITS PHM, et al.Relations between Polymorphisms in Drug-Metabolising Enzymes and Toxicity of Chemotherapy with Cyclophosphamide, Thiotepa and Carboplatin[J]. Pharmacogenetics and Genomics, 2008, 18: 1009-1015.